Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $254.5 million.

  • Mirum Pharmaceuticals' Non-Current Assets fell 950.24% to $254.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 104.12%. This contributed to the annual value of $278.0 million for FY2024, which is 728.96% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Non-Current Assets stood at $254.5 million for Q3 2025, which was down 950.24% from $272.4 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Non-Current Assets' 5-year high stood at $292.9 million during Q2 2024, with a 5-year trough of $4.5 million in Q1 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $162.7 million (2022), whereas its average is $180.9 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 273692.96% in 2021, then tumbled by 5995.01% in 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Non-Current Assets (Quarter) stood at $128.1 million in 2021, then grew by 27.04% to $162.7 million in 2022, then soared by 59.26% to $259.1 million in 2023, then rose by 7.29% to $278.0 million in 2024, then dropped by 8.43% to $254.5 million in 2025.
  • Its last three reported values are $254.5 million in Q3 2025, $272.4 million for Q2 2025, and $279.4 million during Q1 2025.